

AMENDMENTS TO THE CLAIMS

Claims 1-18 cancelled.

19. (New) Fusion protein comprising at least (a) a scFv-part of an antibody, and (b) a cell penetrating transport peptide.

20. (New) Fusion protein comprising at least (a) a scFv-part of an antibody recognising an intracellular GLI-protein, chosen from GLI-1 and GLI-3, and (b) a cell penetrating transport peptide.

21. (New) Fusion protein according to claim 19, wherein the cell-penetrating transport peptide comprises at least a part of Transportan, Transportan 10 or Arg 9.

22. (New) Fusion protein according to any one of claims 19 to 21, wherein the scFv-part is derived from the human genome.

23. (New) Fusion protein according to claim 19, for medical use.

24. (New) Use of the fusion protein according to claim 19, for the preparation of a medicament for treatment of a cancer state.

25. (New) Use according to claim 23, wherein the cancer state is chosen from skin cancer.

26. (New) Pharmaceutical composition comprising at least one fusion protein as defined in claim 19, in association with at least one pharmaceutically acceptable carrier or additive.

27. (New) Method for obtaining a fusion protein as defined in claim 19, wherein the method comprises the steps of expressing the fusion protein and purifying the obtained fusion protein.

28. (New) Method for treatment of a disease or health disorder in humans or animals, comprising administering a pharmaceutically acceptable dose of the fusion protein as defined in claim 19 to humans or animals.